Pet owners have quietly started asking a very human question about their dogs and cats: not just "how do I treat this illness?" but "how do I help them stay healthy longer?" That shift — from reactive veterinary care to proactive health span management — is fueling a fast-emerging category called pet longevity therapeutics, and according to Grand View Research's latest industry analysis, it's moving from niche to notable.

Market Valuation and Projections

The numbers tell a clear growth story. The global pet longevity therapeutics market:

• 2025 market size: $577.6 million
• 2026 estimated market size: $621.6 million
• 2033 projected market size: $1,145.9 million
• CAGR (2026–2033): roughly 9.13%

What's driving that trajectory isn't a single trend but several converging ones. Geroscience research has matured to the point where core biological drivers of aging — mitochondrial dysfunction, NAD+ depletion, mTOR dysregulation, cellular senescence, chronic inflammation — are now understood to be conserved across species, including dogs and cats. That's given supplement and pet-food formulators a credible scientific basis for building products around ingredients like NMN/NR, SIRT activators, and mitochondrial cofactors, rather than marketing around vague "wellness" claims.

Layered on top of that is a consumer behavior shift. Millennial and Gen Z pet owners — now the fastest-growing ownership demographic — are treating their pets more like family members whose long-term health is worth premium spending. That "pet humanization" dynamic, combined with subscription-based direct-to-consumer platforms that turn one-time purchases into ongoing regimens, has created durable, repeat-purchase demand.

Geographically, North America leads with a 39.3% revenue share in 2025, thanks to mature veterinary infrastructure, an active DTC e-commerce ecosystem, and early regulatory engagement from the FDA on longevity drug pathways. But Asia Pacific is the fastest-growing region, projected at a 10.2% CAGR, powered by rising pet ownership in China, India, Japan, and Australia and the cross-pollination of human longevity trends into pet care.

By product type, supplements dominate, holding 68.7% of 2025 revenue — chews, capsules, and powders are simply easier to bring to market than clinically substantiated therapeutic foods, which explains why supplements are also expected to grow fastest going forward.

Want the full breakdown? Explore the complete Pet Longevity Therapeutics Market report for detailed segmentation, country-level forecasts, and a free sample download.

Competitive Landscape & Frontrunners

This is a market with no single company running away with it — Grand View Research characterizes it as moderately fragmented, and the competitive dynamics reflect a coexistence of two very different kinds of players.

On one side are the established pet nutrition giants — Nestlé S.A., Hill's Pet Nutrition, and Royal Canin — which hold structural advantages through veterinary channel access and therapeutic food distribution infrastructure that would take newcomers years to replicate.

On the other side are specialized, longevity-focused entrants gaining real traction through DTC and e-commerce channels, including Zesty Paws, Thorne Vet, and Nutramax Laboratories, alongside a broader roster of profiled companies such as Leap Years, RENUE BY SCIENCE, PurePet, Quincy Bioscience, Antinol, La Petite Labs, Arterra, PETMADE, Petlio, Kormotech, Animal Essentials, Vitality Science, and Longevity for Animals.

Then there's a third category worth watching closely even though it isn't yet generating commercial revenue: pre-commercial pipeline developers. Loyal, a clinical-stage canine longevity drug company, is the standout here. Its pipeline includes:

• LOY-002 — a daily chewable pill targeting metabolic aging in senior dogs, currently in a pivotal trial with an FDA Expanded Conditional Approval submission underway
• LOY-001 — a long-acting injectable for large and giant breed dogs aimed at closing the lifespan gap larger dogs face, with conditional approval pending
• LOY-003 — a daily oral prescription pill targeting the same growth-hormone-linked aging mechanisms as LOY-001, in a self-administered format

Loyal isn't selling products yet, but it's shaping the entire category's evidence standards. In February 2026 the company closed a $100 million Series C round, led by age1 and Baillie Gifford, bringing its total capital raised since 2019 past $250 million. Its FDA conditional approval pathway is establishing regulatory precedent that commercial supplement and food makers are already borrowing from when they design formulations and substantiate claims.

M&A activity is still nascent but directionally telling — larger pet nutrition and animal health conglomerates are increasingly eyeing longevity-branded supplement companies as acquisition targets, particularly those with proprietary formulations, subscription-based customer bases, or veterinary partnerships already in place.

Underdeveloped Opportunities

For all the momentum, several corners of this market remain genuinely underbuilt — which is exactly where the next wave of growth is likely to come from.

Feline-specific formulations. The canine segment leads today, propelled by high-profile programs like the Dog Aging Project and Loyal's pipeline, which have made "dog longevity" a recognizable concept to consumers. Cats have been left behind — despite facing their own well-documented aging conditions like cognitive dysfunction, chronic kidney disease, and cardiometabolic decline. Palatability-optimized, feline-dosed longevity products remain a comparatively open lane.

Therapeutic foods versus supplements. Supplements are easy to launch; therapeutic foods require real clinical substantiation. That gap is exactly why therapeutic food is only the second-fastest-growing product segment today — but as veterinary hospital and clinic pharmacy channels increasingly fold aging-pathway diets into senior wellness protocols, the manufacturers willing to invest in the clinical work now have room to build a defensible moat later.

Cardiometabolic and renal indications. Cognitive aging currently commands the largest indication share simply because cognitive decline is visible and easy for owners to observe. Meanwhile, cellular energy and metabolic resilience — fueled by NAD+ and mitochondrial-support science borrowed from the human longevity space — is the fastest-growing indication. That leaves cardiometabolic and renal aging pathways comparatively underexploited, even though they represent major causes of age-related decline in both dogs and cats.

Emerging markets beyond the obvious. North America and Western Europe have the infrastructure, but markets like India, Brazil, and the Gulf states are still in early-stage development — held back less by demand than by underdeveloped DTC and veterinary distribution. Companies willing to build category education and distribution ahead of the curve in these regions could establish first-mover advantages before larger players arrive.

Ingredient-supply partnerships. A notable recent move came from Together Ever, which in March 2026 launched Revionyx — a B2B longevity ingredient platform designed to let existing pet food and supplement manufacturers integrate aging-pathway science without reformulating from scratch. That "picks and shovels" approach — supplying validated ingredients to established brands rather than competing as a consumer brand — is itself an underdeveloped strategic lane in a market still dominated by direct-to-consumer plays.

The Takeaway

The pet longevity therapeutics market sits at an interesting inflection point: the science has matured enough to be commercially credible, consumer willingness to pay has caught up, but the competitive field is still open enough that positioning — not just product — will determine who captures the next leg of growth. Whether that's an ingredient supplier riding the B2B wave, a feline-focused challenger, or a pipeline biotech turning FDA precedent into category-defining evidence standards, the underdeveloped corners of this market may end up mattering as much as its headline growth rate.

Ready to dig deeper? Request a free sample of the full market report or speak with an analyst to explore custom data for your business.